fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix) (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

Fibric acid derivatives may increase the adverse effects of colchicine (Colcrys) on muscle tissue.

Cyclosporine may increase the toxic effects of fibric acid derivatives on the kidney while fibric acid derivatives may decrease blood levels of cyclosporine.

Fenofibrate and its derivatives may increase the adverse effects associated with ezetimibe (Zetia), HMG-CoA reductase inhibitors (statins), and sulfonlyureas. Fibric acid derivatives may increase the anticoagulation (blood-thinning) benefits of warfarin (Coumadin).

PREGNANCY: Fenofibrate is classified as pregnancy category C. Use of fenofibrate in pregnant females has not been adequately evaluated. Fenofibrate should be avoided during pregnancy unless the benefits justify the potential risk to the fetus.

NURSING MOTHERS: Fenofibrate should not be used in nursing mothers; however, it is unknown whether fenofibrate is excreted into breast milk.

SIDE EFFECTS: Common adverse effects of fenofibrate are abnormal liver tests including AST and ALT, and headache. Less common side effects are high blood pressure, dizziness, itching, nausea, upset stomach (dyspepsia), constipation, diarrhea, urinary tract infections, flu (influenza), muscle pain, kidney problems, and respiratory tract infections.


FDA Prescribing Informaiton.

UpToDate. Lipid lowering with fibric acid derivatives.

Medically Reviewed by a Doctor on 11/11/2014

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index

Health Solutions From Our Sponsors